Literature DB >> 8103076

Brain banks: the Oxford experience.

M M Esiri1.   

Abstract

The organisation value and problems related to the setting up and running of Oxford brain banks to investigate Alzheimer's disease, Creutzfeldt-Jakob disease and AIDS are described. Most neuropathology departments have some sort of brain bank consisting of stored, fixed brains with microscopic sections prepared from selected parts of them to enable a neuropathological diagnosis to be made. Such routine stores are invaluable to return to in order that cases of particular conditions can be collected together and systematically studied. This was, indeed, the classical neuropathological method of research. Modern techniques of immunocytochemistry, applied if necessary after pretreatment of material to restore immunoreactivity of antigens, and of nucleic acid retrieval have enabled such routinely fixed material to be frequently put to further good use in ways previously never thought of to enhance understanding of neuropsychiatric disease. However, such neuropathology stores, or archives, are not quite what is meant normally by a brain bank. This latter term is generally used to refer to brain tissue stored additionally as frozen samples appropriate for a wide range of investigations, particularly biochemical ones. It is with this type of brain bank that this chapter is concerned. The development of brain banks has occurred mainly since the mid-1970's when it was demonstrated that post mortem brain samples could yield important information about many biochemical processes (Bowen et al., 1976). Most brain banks were developed initially to serve the research needs of their own neuropathologists and their immediate collaborators but surplus material was generally also made available to others.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8103076

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  3 in total

1.  Parallel profiling of DNA methylation and hydroxymethylation highlights neuropathology-associated epigenetic variation in Alzheimer's disease.

Authors:  Adam R Smith; Rebecca G Smith; Ehsan Pishva; Eilis Hannon; Janou A Y Roubroeks; Joe Burrage; Claire Troakes; Safa Al-Sarraj; Carolyn Sloan; Jonathan Mill; Daniel L van den Hove; Katie Lunnon
Journal:  Clin Epigenetics       Date:  2019-03-21       Impact factor: 6.551

2.  Increased DNA methylation near TREM2 is consistently seen in the superior temporal gyrus in Alzheimer's disease brain.

Authors:  Adam R Smith; Rebecca G Smith; Daniel Condliffe; Eilis Hannon; Leonard Schalkwyk; Jonathan Mill; Katie Lunnon
Journal:  Neurobiol Aging       Date:  2016-07-16       Impact factor: 4.673

3.  Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease.

Authors:  Katie Lunnon; Rebecca Smith; Eilis Hannon; Philip L De Jager; Gyan Srivastava; Manuela Volta; Claire Troakes; Safa Al-Sarraj; Joe Burrage; Ruby Macdonald; Daniel Condliffe; Lorna W Harries; Pavel Katsel; Vahram Haroutunian; Zachary Kaminsky; Catharine Joachim; John Powell; Simon Lovestone; David A Bennett; Leonard C Schalkwyk; Jonathan Mill
Journal:  Nat Neurosci       Date:  2014-08-17       Impact factor: 24.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.